CMB International Foresees Accelerated Fundamental Improvement in China's Healthcare Sector, Recommends Buying Innovent Bio, 3SBIO, and Others

Stock News15:20

According to a research report from CMB International, the MSCI China Healthcare Index has risen 0.6% since the beginning of 2026, outperforming the MSCI China Index by 3.5 percentage points. The healthcare sector has recently experienced a significant correction, particularly in the innovative drug segment. However, following the recent government work report's designation of biopharmaceuticals as an emerging pillar industry, risk appetite in the sector has shown moderate recovery. The institution believes this elevation in policy positioning signifies the healthcare industry's transition from a "strategic emerging industry" to an "emerging pillar industry," indicating that policy benefits will continue to be released across the entire value chain. Concurrently, breakthroughs in AI-driven drug development technology and the surge in overseas business development by Chinese innovative drug companies are creating dual positive momentum. CMB International anticipates an acceleration in the sector's fundamental improvement. The report recommends buying Innovent Bio (01801), 3SBIO (01530), Jacobio-B (01167), Gushengtang (02273), and Wuxi XDC (02268), with target prices of HK$110.62, HK$37.43, HK$10.34, HK$44.95, and HK$88, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165555890?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 15:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165555890","market":"other","top_or_hot":-1,"title":"CMB International Foresees Accelerated Fundamental Improvement in China's Healthcare Sector, Recommends Buying Innovent Bio, 3SBIO, and Others","media":"Stock News","content":"<p>According to a research report from CMB International, the MSCI China Healthcare Index has risen 0.6% since the beginning of 2026, outperforming the MSCI China Index by 3.5 percentage points. The healthcare sector has recently experienced a significant correction, particularly in the innovative drug segment. However, following the recent government work report's designation of biopharmaceuticals as an emerging pillar industry, risk appetite in the sector has shown moderate recovery. The institution believes this elevation in policy positioning signifies the healthcare industry's transition from a \"strategic emerging industry\" to an \"emerging pillar industry,\" indicating that policy benefits will continue to be released across the entire value chain. Concurrently, breakthroughs in AI-driven drug development technology and the surge in overseas business development by Chinese innovative drug companies are creating dual positive momentum. CMB International anticipates an acceleration in the sector's fundamental improvement. The report recommends buying Innovent Bio (01801), 3SBIO (01530), Jacobio-B (01167), Gushengtang (02273), and Wuxi XDC (02268), with target prices of HK$110.62, HK$37.43, HK$10.34, HK$44.95, and HK$88, respectively.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CMB International Foresees Accelerated Fundamental Improvement in China's Healthcare Sector, Recommends Buying Innovent Bio, 3SBIO, and Others</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCMB International Foresees Accelerated Fundamental Improvement in China's Healthcare Sector, Recommends Buying Innovent Bio, 3SBIO, and Others\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-17 15:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to a research report from CMB International, the MSCI China Healthcare Index has risen 0.6% since the beginning of 2026, outperforming the MSCI China Index by 3.5 percentage points. The healthcare sector has recently experienced a significant correction, particularly in the innovative drug segment. However, following the recent government work report's designation of biopharmaceuticals as an emerging pillar industry, risk appetite in the sector has shown moderate recovery. The institution believes this elevation in policy positioning signifies the healthcare industry's transition from a \"strategic emerging industry\" to an \"emerging pillar industry,\" indicating that policy benefits will continue to be released across the entire value chain. Concurrently, breakthroughs in AI-driven drug development technology and the surge in overseas business development by Chinese innovative drug companies are creating dual positive momentum. CMB International anticipates an acceleration in the sector's fundamental improvement. The report recommends buying Innovent Bio (01801), 3SBIO (01530), Jacobio-B (01167), Gushengtang (02273), and Wuxi XDC (02268), with target prices of HK$110.62, HK$37.43, HK$10.34, HK$44.95, and HK$88, respectively.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1165555890","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165555890","pubTimestamp":1773732029,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to a research report from CMB International, the MSCI China Healthcare Index has risen 0.6% since the beginning of 2026, outperforming the MSCI China Index by 3.5 percentage points. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159891":"医疗","BK1583":"高瓴概念","SG9999014674.SGD":"Nikko AM All China Equity A SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","01530":"三生制药","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","02273":"固生堂","BK1589":"北水核心资产","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1219":"保健护理服务","BK1141":"生命科学工具和服务","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","BK1161":"生物科技","BK1593":"医美概念股","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","01167":"加科思-B","02268":"药明合联","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","01801":"信达生物","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","BK1574":"生物医药B类股"},"translate_title":"招银国际预计中国医疗保健行业基本面加速改善，建议买入信达生物、三生制药等","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159891":1,"01801":1,"02268":1,"01530":1,"01167":1,"02273":1},"content_text":"According to a research report from CMB International, the MSCI China Healthcare Index has risen 0.6% since the beginning of 2026, outperforming the MSCI China Index by 3.5 percentage points. The healthcare sector has recently experienced a significant correction, particularly in the innovative drug segment. However, following the recent government work report's designation of biopharmaceuticals as an emerging pillar industry, risk appetite in the sector has shown moderate recovery. The institution believes this elevation in policy positioning signifies the healthcare industry's transition from a \"strategic emerging industry\" to an \"emerging pillar industry,\" indicating that policy benefits will continue to be released across the entire value chain. Concurrently, breakthroughs in AI-driven drug development technology and the surge in overseas business development by Chinese innovative drug companies are creating dual positive momentum. CMB International anticipates an acceleration in the sector's fundamental improvement. The report recommends buying Innovent Bio (01801), 3SBIO (01530), Jacobio-B (01167), Gushengtang (02273), and Wuxi XDC (02268), with target prices of HK$110.62, HK$37.43, HK$10.34, HK$44.95, and HK$88, respectively.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165555890","isCrawlerRequest":true}